TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19726292
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation of ziprasidone (40 mg)
Study: 19726292
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of ziprasidone (40 mg)
Study: 19726292
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and reference preparations of ziprasidone
Study: 17846399
Drug: Bupropion hydrochloride,
Normalized name: BuPROPion Hydrochloride, 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion hydrochloride, 150 mg twice a day
Study: 15500895
Drug: Regularly scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly scheduled albuterol treatment
Study: 15500895
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of albuterol vs placebo
Study: 11686808
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (SU)
Study: 7934734
Drug: Antinicotinic therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinicotinic therapeutic films containing anabasinum, cytisinum, or their combination in equal ratios applied to the gingiva beneath the upper lip.
Study: 7934734
Drug: Antinicotinic therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinicotinic therapeutic films containing cytisinum and anabasinum in combination or cytisinum alone.
Study: 3602023
Drug: Commercially-available bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially-available bowel evacuant kit (magnesium citrate oral solution, phenolphthalein tablets, bisacodyl suppository)
Study: 28825891
Drug: Probucol (cholesterol-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (cholesterol-lowering agent) treatment for 6 months
Study: 23907204
Drug: WBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT + TMZ 75 mg/m² for 2 weeks followed by TMZ 100 mg/m²/day 2 weeks on/2 weeks off for up to 6 months (RCT)
Study: 21079746
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) and betaine with pegIFNα2b and ribavirin
Study: 10376694
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (9 subjects)
Study: 10376694
Drug: Multiple treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple treatments (58 subjects)
Study: 8905942
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture of lidocaine and tetracaine (LT ointment) applied 1-2 h before block (group 3)
Study: 8905942
Drug: Midazolam 5
Normalized name: midazolam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 5 mg intramuscularly (groups 2 and 3)
Study: 367057
Drug: Oxazepam 15
Normalized name: oxazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 15 mg
Study: 7144761
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (20 mg/kg i.m. daily during artificial ventilation for up to 14 days)
Study: 28755266
Drug: Latiglutenase (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latiglutenase (900 mg, n=14)
Study: 25823136
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment in addition to dexamethasone and methycobal; chiropractic included local muscle loosening, attacking point, bilateral pulling atlanto-axial joint, continuous treatment for 10 days.
Study: 25823136
Drug: Dexamethasone intravenous
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone intravenous drip of 10 mg for 3 days, decreased to 5 mg for another 3 days; methycobal intravenous drip of 500 μg for 10 days.
Study: 18085028
Drug: Prilocaine plus
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine plus meperidine (Group MP): 5 ml fluid combination containing prilocaine (10 mg/ml) and meperidine (1 mg/kg) injected into nasal packs 15 minutes before removal
Study: 18085028
Drug: Prilocaine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (Group P): 5 ml of 1% prilocaine in saline injected into the pack 15 minutes before removal
Study: 18085028
Drug: Control: 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: 5 ml saline injected into the contra-lateral nostril in both groups
Study: 23412704
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg single dose
Study: 23412704
Drug: Placebo 500
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg single dose
Study: 18461849
Drug: Interdisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary treatment at the Basel clinic
Study: 17078217
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of bone marrow autologous mononuclear cells (BMAMC) after stenting the coronary artery, performed on AMI day 7-21.
Study: 17078217
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BMAMC treatment).
Study: 8883532
Drug: Iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol at 270 mg I/ml
Study: 8883532
Drug: Iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol at 320 mg I/ml
Study: 8883532
Drug: Iohexol at
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol at 300 mg I/ml
Study: 4003142
Drug: 1.32 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.32 mg/kg of 95% USP alcohol
Study: 30553555
Drug: Low-dose (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (150 mg) pregabalin
Study: 30553555
Drug: High-dose (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (300 mg) pregabalin
Study: 22496401
Drug: Early-invitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-invitation group (started receiving food supplements at 9 weeks gestation)
Study: 22496401
Drug: Usual-invitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-invitation group (started receiving food supplements at 20 weeks gestation)
Study: 17380562
Drug: Transfusion Risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion Risk Score (TRS) based on clinicopathological factors including preoperative haemoglobin concentration below 12.5 g/dl, largest tumour more than 4 cm, need for exposure of the vena cava, need for an associated procedure, and cirrhosis.
Study: 12374430
Drug: Cellular replacement
Normalized name: ISOLYTE E EXTRACELLULAR REPLACEMENT SOLN,INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular replacement therapy using mesencephalic brain cells from fetal cadavers
Study: 9520913
Drug: Theophylline (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (plasma concentrations between 15-20 micrograms/ml)
Study: 2702169
Drug: Fluoride iontophoresis
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride iontophoresis (initial treatment)
Study: 2702169
Drug: Fluoride iontophoresis
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride iontophoresis (second treatment after 4 weeks)
Study: 4753234
Drug: Diazepam administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam administration (30 mg or less)
Study: 4753234
Drug: Diazepam administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam administration (larger doses)
Study: 23773310
Drug: Morning bright-light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning bright-light therapy (10,000 lux)
Study: 21612143
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg/Kg
Study: 21612143
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/Kg
Study: 21612143
Drug: Ketamine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.125 mg/Kg
Study: 23469326
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS)
Study: 16796730
Drug: WS 5570
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 5570 600 mg/day and WS 5570 1200 mg/day
Study: 19777696
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon-alpha (HD IFN)
Study: 9404441
Drug: Pituitary stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pituitary stimulation tests (GnRH and TRH injections)
Study: 24060588
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (ADM) alone or in combination with CT or IPT
Study: 24060588
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (ADM + CT or IPT)
Study: 20564094
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg) plus dexamethasone (40 mg)
Study: 18501073
Drug: Continuous 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 5‐FU infusion plus oxaliplatin (n = 23)
Study: 18501073
Drug: Weekly 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5‐FU bolus with LV plus oxaliplatin (n = 40)
Study: 18501073
Drug: Oxaliplatin with
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin with 2‐day infusion 5‐FU/LV (FOLFOX4, n = 41)
Study: 8758503
Drug: Lactulose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (20 mg) taken in one intake
Study: 8758503
Drug: Lactulose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (20 mg) taken in two intakes
Study: 8758503
Drug: Lactulose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (20 mg) in both one and two intakes
Study: 6110188
Drug: Dihydergot plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydergot plus (combination of dihydroergotamine and etilefrine)
Study: 6110188
Drug: Dihydroergotamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (2 mg, 3 times daily)
Study: 6110188
Drug: Etilefrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine (20 mg, 3 times daily)
Study: 31047819
Drug: Combination HAL‐SJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HAL‐SJ and occupational therapy
Study: 25723140
Drug: Maternal ARV
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal ARV treatment
Study: 15202047
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (group 3)
Study: 10509038
Drug: Standard melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard melphalan and prednisone (MP) chemotherapy
Study: 10509038
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) in poor prognosis patients with high LI (>1.2%)
Study: 10509038
Drug: Standard melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard melphalan and prednisone (MP) chemotherapy in poor prognosis patients with high LI (>1.2%)
Study: 10509038
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) in poor prognosis patients with high β2-M (> 3 mg/L)
Study: 8949385
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg/day (initial treatment)
Study: 8949385
Drug: Treatment across
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment across different geographic areas (Northern Europe vs Southern Europe)
Study: 8949385
Drug: Treatment across
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment across different genders
Study: 8949385
Drug: Time and
Normalized name: DayTime and NiteTime KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time and number of antihypertensive drugs
Study: 7340880
Drug: Cimetidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1000 mg daily)
Study: 7340880
Drug: Cimetidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1000 mg daily for 5 days)
Study: 31640241
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2800 IU daily)
Study: 26892413
Drug: Peak Vo2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak Vo2 (ml·kg(‐1)·min(‐1))
Study: 22450017
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g of lactose in 250 cc water
Study: 22450017
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g of maltose in 250 cc water
Study: 17400977
Drug: Amiodarone (AMIO)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone (AMIO) 600 mg orally for seven days before surgery and 45 mg/hr intravenously for 48 hr postoperatively
Study: 12015692
Drug: Ertapenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1 g once daily)
Study: 16048928
Drug: Piperacillin-tazobactam (3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (3.375 g every 6 h)
Study: 8556971
Drug: Paroxetine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10, 20, 50 mg)
Study: 30619887
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose carvedilol (3.125 mg twice daily) for 1 week
Study: 19269519
Drug: Selective postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective postoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent 5-fluorouracil; n=676)
Study: 11242378
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy (anesthetics, steroids, or both)
Study: 9644527
Drug: 7-day switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day switch therapy with parenteral cefuroxime 750 mg for 3-5 days followed by oral cefuroxime axetil 500 mg every 12 hours
Study: 9644527
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy with parenteral cefuroxime 750 mg every 8 hours
Study: 27838347
Drug: Fluticasone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone treatment for 6 weeks
Study: 26268314
Drug: PanAd3‐RSV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PanAd3‐RSV vaccine
Study: 26268314
Drug: PanAd3‐RSV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PanAd3‐RSV vaccine in combination with MVA‐RSV
Study: 10391070
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at a dosage of 4 mg/kg/day
Study: 10391070
Drug: Transfer Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer Factor (TF) with one unit every third day for the first week, two units per week for the next three weeks, and one monthly unit for six months
Study: 2050157
Drug: Metoclopramide cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide cocktail (10 mg/kg) with betamethasone (20 mg) and biperiden (5 mg)
Study: 2050157
Drug: Dixyrazine combination
Normalized name: dixyrazine
DrugBank: Dixyrazine (DB13784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixyrazine combination (240 mg) with betamethasone (20 mg) and biperiden (5 mg)
Study: 2050157
Drug: Dixyrazine combination
Normalized name: dixyrazine
DrugBank: Dixyrazine (DB13784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixyrazine combination (240 mg)
Study: 2050157
Drug: Metoclopramide cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide cocktail (10 mg/kg)
Study: 6617071
Drug: Codeine sulfate,
Normalized name: Codeine Sulfate, sulfate 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine sulfate, 60 mg
Study: 6617071
Drug: Codeine sulfate,
Normalized name: Codeine Sulfate, sulfate 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine sulfate, 120 mg
Study: 3552360
Drug: Aspirin, 650
Normalized name: Aspirin, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 650 mg
Study: 10711416
Drug: Fenofibrate therapy
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate therapy
Study: 30409160
Drug: Gram stain-guided
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gram stain-guided initial antibiotic treatment
Study: 30409160
Drug: Guidelines-based initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines-based initial antibiotic treatment
Study: 30409160
Drug: Gram stain-guided
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gram stain-guided treatment
Study: 30409160
Drug: Guidelines-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines-based treatment
Study: 25324159
Drug: Early Childhood
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Childhood Oral Health Impact Scale (ECOHIS)
Study: 22495093
Drug: Physio Acoustic
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physio Acoustic Sound (PAS) therapy, applied for 30 minutes on a mattress with an in-built PAS device during the intervention period.
Study: 22495093
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PAS therapy), measurements continued without intervention during the wash-out period.
Study: 21393298
Drug: Eplerenone 25-50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25-50 mg/day
Study: 17604563
Drug: LA (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA (600 mg/day)
Study: 11224984
Drug: New approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: New approaches to treatment based on immune system recognition of genetic alterations
Study: 7999408
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Study: 7999408
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Study: 7999408
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Study: 7999408
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg fadrozole hydrochloride (CGS 169 49A) daily
Study: 7999408
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of fadrozole hydrochloride
Study: 28776408
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 10 treatments of invisible infrared laser (904 nm, 3 Joules/point) over three weeks followed by an eight-week supervised strengthening exercise program
Study: 28776408
Drug: Placebo LLLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LLLT (identical treatment with disabled infrared laser output)
Study: 26973326
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with exercise (MT+Ex)
Study: 26973326
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with exercise without boosters (MT+Ex)
Study: 26973326
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with exercise with boosters (MT+Ex+B)
Study: 20116457
Drug: Enhanced Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Medical Management (EMM; SMM plus individual drug counseling)
Study: 16186674
Drug: Oral butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral butorphanol 0.2 mg/kg
Study: 19546692
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg/kg
Study: 10663451
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg as single oral dose at 2200 hours)
Study: 8880941
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg nicotine
Study: 8880941
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg nicotine
Study: 6486761
Drug: Ribavirin aerosol
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin aerosol treatment
Study: 31040088
Drug: Mannitol, 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol, 0.25 g/kg/h
Study: 24999797
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 8 weeks
Study: 22250032
Drug: IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG treatment after day 10
Study: 22250032
Drug: IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG treatment before day 10 (control)
Study: 16890688
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg daily)
Study: 15709841
Drug: Behavioral couple
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couple therapy for infidelity couples
Study: 10814600
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg)